Personalized medicine: Boon or budget-buster?

Annals of Pharmacotherapy

Volumn 43, Issue 5, 2009, Pages 958-962

  Dean, Charles E ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c Department 116A ^*  (United States)

Author keywords

Personalized medicine; Pharmacoeconomics; Pharmacogenomics

Indexed keywords

DNA;

COST BENEFIT ANALYSIS; ECONOMIC ASPECT; ENVIRONMENTAL FACTOR; EPIGENETICS; GENETIC VARIABILITY; HEREDITY; NOTE; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION;

ANTIPSYCHOTIC AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; GENOMICS; HEALTH CARE COSTS; HUMANS; PHARMACOGENETICS; SOCIOECONOMIC FACTORS;

EID: 65749090996     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L563     Document Type: Note

References (34)

1. Evans WE, Relling M. Moving toward individualized medicine with pharmacogenomics. Nature 2004;429:464-468 (Pubitemid 38715141)
2. Cacabelos R, Llovo R, Fraile C, Fernandez-Novoa L. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics. Curr Alzheimer Res 2007;4: 479-500. (Pubitemid 47416643)
3. Candore G, Balistreri CR, Caruso M, et al. Pharmacogenomics: a tool to prevent and cure coronary artery disease. Curr Pharmaceut Design 2007; 13:3726-3734
4. Lippi G, Franchini M, Montagnana M, Guidi GC. Genomics and proteomics in venous thromboembolism: building a bridge toward a rational personalized medicine framework. Sem Thromb Hemost 2007;33:759-770
5. Malhotra AK, Lencz T, Correll CU, Kane JM. Genomics and the future of pharmacotherapy in psychiatry. Int Rev Psychiatry 2007;19:523-530 (Pubitemid 47493739)
6. Lewis S, Lieberman J. CATIE and CUtLASS: can we handle the truth? Brit J Psychiatry 2008:192:161-163
7. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia. BMJ 2002;325:243-245
8. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27: 596-601.
9. Mackin P, Bishop D, Watkinson H, Gallagher P, Ferrier N. Metabolic disease and cardiovascular risks in people treated with antipsychotics in the community. Brit J Psychiatry 2007;191:23-29 (Pubitemid 47035177)
10. de Leon J. Beyond the "hype" on the association between metabolic syndrome and atypical antipsychotics: the confounding effects of cohort, typical antipsychotics, severe mental illness, comedications, and comorbid substance abuse (guest editorial). J Clin Psychopharmacol 2008;28: 125-131
11. Cravchik A, Goldman D. Neurochemical individuality: genetic diversity among human dopamine and serotonergic receptors and transporters. Arch Gen Psychiatry 2000;57:1105-1114
12. The International Schizophrenia Consortium. Rare chromosomal deletions and duplications increase the risk for schizophrenia. Nature. Epub 2008;455:237-41. DOI 10.1038/nature07239. www.nature.com/nature/ journal/vaop/ncurrent/abs/nature07239.html (accessed 2008 Aug 20).
13. van der Kam EL, Ellenbroek BA, Cools AR. Gene-environment interactions determine the individual variability in cocaine self-administration. Neuropharmacol 2005;48:685-695 (Pubitemid 40462408)
14. Westenbroeck C, Den Boer JA, Veenhuis M, et al. Chronic stress and social housing differentially affects neurogenesis in male and female rats. Brain Res Bull 2004;64:303-308
15. Son GH, Geum D, Chung S, et al. Maternal stress produces learning deficits associated with impairment of NMDA receptor-mediated synaptic plasticity. J Neurosci 2006;26:3309-3318
16. Seckfort DL, Paul R, Grieve SM, et al. Early life stress on brain function and structure across the life span: a preliminary study. Brain Imaging Behav 2008;2:49-58.
17. Arranz MJ, Kapur S. Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophr Bull 2008;34:1130-1144
18. Kovacs KJ, Csejtei M, Lazlovskzy I. Double activity imaging reveals distinct cellular targets of haloperidol, clozapine, and dopamine D (3) receptor selective RGH-1756. Neuropharmacol 2001;40:383-393
19. Cochran SM, McKerchar CE, Morris BJ, Pratt JA. Induction of differential patterns of local cerebral glucose metabolism and immediate-early genes by acute clozapine and haloperidol. Neuropharmacology 2002;43: 394-407. (Pubitemid 35257931)
20. Senn S. Individual response to treatment: is it a valid assumption? BMJ 2004;329:966-968
21. Wade N. Gene-hunters find hope and hurdle in schizophrenia studies. www.nytimes.com/2008/07/31/health/research/31.gene.html (accessed 2008 Aug 13).
22. Waltz E. GlaxoSmithKline cancer drug threatens Herceptin market. Nature Biotechnol 2008;23:1203-1204
23. Pollack A. Cutting dosage of costly drug spurs a debate. www.nytimes. com/2008/03/16/business/16 Gaucher.html (accessed 2008 Mar 26).
24. Kolata G, Pollack A. Costly cancer drug offers hope, but also a dilemma. www.nytimes.com/2008/07/06/health/06avastin.html (accessed 2008 Jul 9).
25. FDA approves Gleevec for leukemia treatment. FDA News. www.fda. gov/bbs/topics/NEWS/2001/NEW00759.html (accessed 2008 Dec 30).
26. Kessler RC, Heeringa S, Lakoma MD, et al. Individual and societal effects of mental disorders on earnings in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2008; 165:703-711
27. Insel TR. Assessing the economic costs of serious mental illness (editorial). Am J Psychiatry 2008;165:663-665
28. Miranda J, McGuire TG, Williams DR, Wang P. Mental health in the context of health disparities. Am J Psychiatry 2008;165:1102-1108
29. Pollack A. California licenses 2 companies to offer gene services. New York Times 2008;Aug 20:C3.
30. Lee C, Morton CC. Structural genomic variation and personalized medicine. N Engl J Med 2007;358:740-741
31. Korbel JO, Urban AE, Affourtit JP, et al. Paired end-mapping reveals extensive structural variation in the human genome. Science 2007;318: 420-426
32. Kaiser J. Departing US genome institute director takes stock of personalized medicine. Science 2008;320:1272.
33. Schmidt C. Newly revealed genomic complexity may mean personalized medicine is farther away. J Natl Cancer Inst 2007;99:1568-1570
34. Insel TR. A new era in psychiatric genetics? Biol Psychiatry 2007;61: 1017-1018